Legochem Biosciences, Inc.

Korea Hydro Nuclear Power Co., Ltd.

Ji Eun Jung

Yong Zu Kim

Ho Young Song

Jeiwook Chae

Chul-Woong Chung

Yun Hee Park

Hyo Jung Choi

Yeong Soo Oh

Sung Min Kim

Dong Hyun Woo

Ji Young Min

Kyung Eun Park

Su In Lee

Hyoungrae Kim

Jinyeong Kim

Byung Soo Lee

Jiyoung Lee

Jeong Hee Ryu

Yonghee Kim

Seongdong Jang

Ur Rehman Haseeb

Young Ae Kim

Eun Ki Lee

The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.

Antibody-drug conjugates comprising branched linkers and methods related thereto

Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.

Method of producing TC-99M by using nuclear resonance fluorescence

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Conjugates comprising self-immolative groups and methods related thereto

Disclosed is an apparatus for extracting multiple laser Compton scattering ('LCS') photon beams using a laser Compton scattering reaction, the apparatus including: a linear accelerator for accelerating an electron beam; and an LCS gamma ray generation module including an LCS gamma ray generator for irradiating a target with an LCS gamma ray generated by emitting laser light to an electron beam released from the linear accelerator and a bending magnet for adjusting a direction of the electron beam passed through the LCS gamma ray generator, wherein at least two LCS gamma ray generation modules are sequentially arranged to form a closed loop together with the linear accelerator.

Apparatus for extracting multiple laser compton scattering photon beams

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Conjugates comprising peptide groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Compositions and methods related to anti-CD19 antibody drug conjugates

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor ('EGFR') antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Compositions and methods related to anti-EGFR antibody drug conjugates

Growing community of inventors

Daejeon, South Korea

Ji Eun Jung